Utilizing T-cell activation signals 1, 2 and 3 for tumor-infiltrating lymphocytes (TIL) expansion: the advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma

In this study, we address one of the major critiques for TIL therapy - the time needed for proper expansion of a suitable product. We postulated that TCR activation in the first phase of expansion combined with an agonistic stimulation of CD137/4-1BB and IL-2 would favor preferential expansion of CD...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother
Asıl Yazarlar: Tavera, René J., Forget, Marie-Andrée, Kim, Young Uk, Sakellariou-Thompson, Donastas, Creasy, Caitlin A., Bhatta, Ankit, Fulbright, Orenthial J., Ramachandran, Renjith, Thorsen, Shawne T., Flores, Esteban, Wahl, Arely, Gonzalez, Audrey M., Toth, Christopher, Wardell, Seth, Mansaray, Rahmatu, Radvanyi, Laszlo G., Gombos, Dan S., Patel, Sapna P., Hwu, Patrick, Amaria, Rodabe N., Bernatchez, Chantale, Haymaker, Cara
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177302/
https://ncbi.nlm.nih.gov/pubmed/29757889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000230
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller